22934-58-3

Basic information

• Product Name: METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE
• Synonyms: METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE;3,4-methylenedioxy-5-methoxy-methly benzoate;1,3-Benzodioxole-5-carboxylic acid, 7-Methoxy-, Methyl ester;3-Methoxy-4,5- (Methylenedioxy)benzoic Acid Methyl Ester;3-Methoxy-4,5-Methylenedioxybenzoic Acid Methyl Ester;7-Methoxy-1,3-benzodioxole-5-carboxylic Acid Methyl Ester;Methyl 7-Methoxybenzo[d][1,3]dioxole- 5-carboxylate;7-Methoxy-benzo[1,3]dioxole-5-carboxylicacidmethylester
• CAS NO: 22934-58-3
• Molecular Formula: C₁₀H₁₀O₅
• Molecular Weight: 210.18
• Mol File: 22934-58-3.mol
• Article Data: 29

Chemical Properties

• Melting Point: 91℃
• Appearance: /
• CAS DataBase Reference: METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE(22934-58-3)
• EPA Substance Registry System: METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE(22934-58-3)

Safety Data

• Hazardous Substances Data: 22934-58-3(Hazardous Substances Data)

Usage

General Description

Methyl 3-methoxy-4,5-methylenedioxybenzoate is a specialized, synthetic chemical compound. As the name suggests, this compound comprises a methyl group, a methoxy group, and a methylenedioxy group, bound to a benzoate backbone. It is important to note that the specific structure of this compound, including the positions and orientations of these chemical groups, are what determine its physical, chemical, and biological properties. Although limited information is available regarding its specific applications, similar structures play a role in industries ranging from pharmaceuticals to plastics. Like all chemicals, appropriate safety measures should be taken while handling and using methyl 3-methoxy-4,5-methylenedioxybenzoate.

Upstream product

• 74-97-5 chlorobromomethane 
• 3934-86-9 methyl 3,4-dihydroxy-5-methoxybenzoate 
• 116119-01-8 methyl 7-hydroxybenzo[d][1,3]dioxole-5-carboxylate 
• 74-88-4 methyl iodide 
• 75-27-4 bromodichloromethane 
• 142531-43-9 methyl 7-(benzyloxy)benzo[d][1,3]dioxole-5-carboxylate 
• 5780-07-4 3-methoxy-4,5-methylenedioxybenzaldehyde 
• 607-91-0 myristicin 
• 487-62-7 isomyristicin 
• 77-78-1 dimethyl sulfate 
• 482627-94-1 7-hydroxy-benzo[1,3]dioxole-5-carboxylic acid 
• 73340-44-0 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone 
• 3934-84-7 3,4-dihydroxy-5-methoxybenzoic acid 
• 526221-05-6 2-ethoxy-7-hydroxy-benzo[1,3]dioxole-5-carboxylic acid methyl ester 

Downstream Products

• 944729-85-5 (E)-6-(3-(benzyloxy)styryl)-4-methoxybenzo[d][1,3]dioxole 
• 944729-95-7 (E)-4-methoxy-6-(3-nitrostyryl)benzo[d][1,3]dioxole 
• 944729-99-1 (E)-6-(4-(benzyloxy)styryl)-4-methoxybenzo[d][1,3]dioxole 
• 944730-03-4 (E)-6-(4-fluorostyryl)-4-methoxybenzo[d][1,3]dioxole 
• 944730-07-8 (E)-6-(4-(benzyloxy)-3-methoxystyryl)-4-methoxybenzo[d][1,3]dioxole 
• 1221717-33-4 3-(3-hydroxy-4-methoxyphenyl)-5-(3-methoxy-4,5-methylenedioxyphenyl)-1,2,4-triazole 
• 1257321-38-2 C₁₇H₁₆N₂O₇ 
• 1257321-39-3 C₁₉H₂₀N₂O₈ 
• 1221721-82-9 2-(3-hydroxy-4-methoxyphenyl)-5-(3-methoxy-4,5-methylenedioxyphenyl)-1,3,4-oxadiazole 
• 1221717-58-3 2-(3,4,5-trimethoxyphenyl)-5-(3-methoxy-4,5-methylenedioxyphenyl)-1,3,4-oxadiazole 
• 81474-47-7 methyl-6-bromo-7-methoxybenzo [d] [1, 3] dioxole-5-carboxylate 
• 81474-46-6 4-bromo-7-methoxybenzo[1,3]dioxole-5-carboxylic acid methyl ester 

Relevant articles and documents

Design, synthesis and anticancer evaluation of novel 1,3-benzodioxoles and 1,4-benzodioxines

A new set of 1,3-benzodioxoles and 1,4-benzodioxines was designed and synthesized starting from gallic acid as anticancer agents. The antiproliferative effect of the target compounds was evaluated against a panel of cancer cell lines (HepG2, PC-3, MCF-7 and A549) using MTT assay. The 1,4-benzodioxine derivative 11a manifested broad spectrum effect towards the four tested cancer cell lines (IC50 50 = 6.37 μM. Also, flow cytometeric analysis revealed that compound 11a could induce both early and late stage apoptosis in MCF-7 cell line. Moreover, the ability of this compound to stimulate apoptosis in the latter cell line was further confirmed by: increment of Bax/Bcl-2 ratio, increase the expression of tumor suppressor gene p53, boosting the levels of initiator and executioner caspases as well as raise in the amount of cytochrome C. In addition molecular docking study was accomplished on the colchicine binding site of tubulin (pdb: 1SA0) to illustrate the interactions of the most potent compound 11a to the receptor.

Design and synthesis of novel parabanic acid derivatives as anticonvulsants

In this work a set of novel derivatives of parabanic acid 9a-d, 12a-d and 13a-d was synthesized and their anticonvulsant potential was evaluated. All the compounds under investigation exhibited anticonvulsant activity in both scPTZ and MES tests. In phase II anticonvulsant study, the trimethoxy phenyl derivative 9a evoked the highest potency among the tested compounds in scPTZ test. It displayed 1.72- and 17.05-folds activity more than the standard drugs phenobarbital and ethosuximide, respectively. In addition, the margin of safety for compound 9a is better than that of the reference antiepileptic drug ethosuximide. Also, compound 9a was devoid of hepatotoxicity indicated by measurements of serum level of ALT, AST, ALP, albumin and total protein. Furthermore, treatment with compound 9a significantly increased the GABA brain level by 2.56-folds compared to the control value. Additionally, molecular docking was performed on the active site of GABA-AT to clarify the interactions of the most potent compound 9a with the enzyme. In MES test, compound 12a exhibited the most potent activity against electric stimuli-induced seizures with the lowest ED50 = 13.7 mg/kg and protective index >36.5. Both candidates 9a and 12a could be a good starting point to develop new molecules as novel antiepileptic drugs.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.